The availability of disease-specific genomic data is critical for developing new computational methods that predict the pathogenicity of human variants and advance the field of precision medicine. However, the lack of gold standards to properly train and benchmark such methods is one of the greatest challenges in the field. In response to this challenge, the scientific community is invited to participate in the Critical Assessment for Genome Interpretation (CAGI), where unpublished disease variants are available for classification by in silico methods. As part of the CAGI-5 Family Foundation Fellowships, Grant/Award Number: R01GM104390 challenge, we evaluated the performance of 18 submissions and three additional methods in predicting the pathogenicity of single nucleotide variants (SNVs) in checkpoint kinase 2 (CHEK2) for cases of breast cancer in Hispanic females. As part of the assessment, the efficacy of the analysis method and the setup of the challenge were also considered. The results indicated that though the challenge could benefit from additional participant data, the combined generalized linear model analysis and odds of pathogenicity analysis provided a framework to evaluate the methods submitted for SNV pathogenicity identification and for comparison to other available methods. The outcome of this challenge and the approaches used can help guide further advancements in identifying SNV-disease relationships.
| INTRODUCTION
Checkpoint kinase 2 (CHEK2) has been demonstrated to be an effector kinase in the DNA damage checkpoint pathway, thus variations in its sequence can lead to detrimental outcomes in downstream DNA replication processes (Chaturvedi et al., 1999) .
CHEK2 alterations by single nucleotide variants (SNVs) are linked to DNA damage that is implicated in cases of breast cancer (BC; Apostolou & Papasotiriou, 2017) . BC is the most commonly diagnosed cancer among female Hispanics in the United States and the leading cause of cancer related deaths (Lynce et al., 2016) . By identifying pathogenic variants could lead to early diagnosis and/or prevention thus reducing mortality.
New methodologies to estimate the impact of variants on disease conditions are crucial for the advance of personal genome interpretation studies (Capriotti, Nehrt, Kann, & Bromberg, 2012; Peterson, Doughty, & Kann, 2013) . These methods can be broadly divided into two categories: data-driven machine learning algorithms or algorithms trained with expert knowledge (Peterson et al., 2013) .
Unfortunately, the results from all these methods are not presented in a consistent way, mostly due to lack of benchmarks to assess the different methodologies (MacArthur et al., 2014; Pejaver, Mooney, & Radivojac, 2017) .
Critical Assessment of Genome Interpretation (CAGI) is a community effort created to address the challenges around the benchmarking of computational methods for predicting phenotypic impacts of genomic variation (https://genomeinterpretation. org/). The purpose of the CAGI challenges is to provide a standardized framework for comparison across these different methodologies to classify human variants.The fifth CAGI experiment involved 14 challenges, one of which was the CHEK2 challenge. The CHEK2 challenge prompted the submitters to assign a p (case) value to a list of provided CHEK2 variants to indicate whether they were protective or not. The p (case) values are numeric values between 0 and 1. A value of .5 would indicate that the variation is neutral (equal in both populations) while a p < .5 would be indicative of a variant that is protective. The CHEK2 protein reference used for this challenge can be found by the NCBI reference sequence ID: NP_001005735.1.
This challenge received 18 entries from eight different groups which were assessed in addition to three publicly available methodologies that differed from the ones used for the submissions: SIFT (Sim et al., 2012) , Align-GVGD (Mathe et al., 2006; Tavtigian et al., 2006) , and Blocks Substitution Matrix (BLOSUM) 62 (Jones, Taylor, & Thornton, 1992; Schwarz & Dayoff, 1979) . We assessed these methods in two ways: (a) by providing a comparison on the performance of each method for each SNV using a generalized linear model (GLM); and (b) by calculating pathogenicity odds for each method. From our analysis, we showed that some methods performed well in both analysis measures, but also that each analysis method provided a different insight into the methodʼs performance. Our GLM p values showed that Group 5.1 performed best followed by the submissions of Group 3. When evaluated on a subgroup, excluding variants with low number of cases/controls, Group 4.1 did best. However, if we considered both the odds of pathogenicity and significance of p values Group 3.1 performed well in both assessment methods.
| MATERIALS AND METHODS

| Data source
The participant CHEK2 data were provided by Dr. Elad Ziv and Dr. Susan Neuhausen, from an R01-funded project of self-identified Hispanic women with BC who previously had tested negative for carrying a BRCA1 or BRCA2 (BRCA) variations. Further inclusion criteria were: age <51 years at BC diagnosis, bilateral BC, breast and ovarian cancer, odds ratio (OR) age at diagnosis between ages 51 and 70 years with a family history of BC in two or more first or second-degree relatives diagnosed at <70 years of age.
Participants had been previously consented and enrolled in VOSKANIAN ET AL. 
| CHEK2 variant data set
The data set included 43 exonic variants and 10 untranslated region variants. Of the variants, 34 were nonsynonymous SNVs, four were synonymous SNVs, one was a stop-gain SNV, two were nonframeshift deletions, and two were frameshift deletions. Submitters only predicted on the 34 exonic nonsynonymous SNVs. A summary of this subset can be seen in Figure 1 . One of the nonsynonymous SNVs was misreported and did not match the amino acid in the reference (NP_001005735.1). For the purposes of the assessment, the misreported variant was adjusted to its correct initial amino acid.
| Reference methods
There are numerous methods available for variation analysis (Peterson et al., 2013; Tavtigian, Greenblatt, Lesueur, & Byrnes, 2008) , some of which were used by the submitters. For the purpose of comparison, we selected the simplest approach a scoring function for amino acid variations regardless of the sequence context, BLOSUM62 (Henikoff & Henikoff, 1992; Jones et al., 1992) , and two more sophisticated approaches that include position specific information and amino acidʼs physicochemical properties into the analysis, SIFT (Sim et al., 2012) and Align-GVGD (Mathe et al., 2006; Tavtigian et al., 2006) , respectively.
| SIFT
SIFT (Sim et al., 2012) is an algorithm that predicts the probability of an amino acid variation affecting protein function.
The algorithm was accessed online, https://sift.bii.a-star.edu.sg/ www/SIFT_seq_submit2.html. The input files were the CHEK2 sequence (NP_001005725.1) in FASTA format and the list of the variants as provided by CAGI. All other parameters were kept as defaults from December 2019. The output from this was a prediction of whether the variant would affect the protein function or not with a score and a confidence indicator.
| Align-GVGD
Align-GVGD was run using the default parameters as presented at http://agvgd.hci.utah.edu/agvgd_input.php. The Align-GVGD program (Mathe et al., 2006; Tavtigian et al., 2006) combines an alignment with amino acid physico-chemical characteristics to calculate the range of variation present at each position in the alignment (GV) and the distance of missense substitutions from that range of variation (GD).
Grades are assigned to each variation to provide an empirical mapping from GV-GD to genetic risk. For this analysis SNVs in C0 were considered benign, C15-C25 were considered indeterminate and C35-C65 were considered pathogenic.
| BLOSUM62
BLOSUM (Henikoff & Henikoff, 1992; Jones et al., 1992) was used to score the amino acid substitutions. Each substitution is given a score indicating the similarity or difference for each variant. BLOSUM62 (Henikoff & Henikoff, 1992; Jones et al., 1992) scores range from −4 to 11. A positive score indicates identity or common substitutions, a score of 0 is a commonly observed neutral substitution and a negative score indicates a rarely observed substitution, for this purpose assumed to be nonprotective. The more negative the BLOSUM62 substitution score is, the more likely it is that the variant results in a functionally significant, pathogenic, alteration of the protein.
| Submissions
For this challenge, CAGI received 18 submissions from eight different groups. The participating methods relied on evolutionary information, structural information, and machine learning approaches, providing predictions for all the 34 nonsynonymous SNVs. Only one method did not report a result for the misreported position, however, we estimated that this would not have significantly altered the assessment outcomes. Below is a brief description of each the methodologies that participated in this challenge provided by each submission group. The authors responsible for each submission are also provided as well as a link to the algorithms used, when available.
| Methodologies used by Group 1 (Olivier Lichtarge, Panagiotis Katsonis)
Available for nonprofit use at http://mammoth.bcm.tmc.edu/
EvolutionaryAction
The Evolutionary Action (EA) measures the fitness effect of coding variations analytically from protein evolution data (Katsonis & Lichtarge, 2014) , in the scale of 0 (benign) to 100 (pathogenic). The EA scores were used to calculate the p (case) that a CHEK2 variant is seen in cases rather than in controls. Ideally, benign variants are expected to be seen either in cases or in controls, while pathogenic variants are expected to be seen only in cases. Therefore, the EA scores were linearly transformed between 0.5 and 1, using:
The input of EA was 60 homologous sequences of the human CHEK2 sequence (NP_009125). The homologous CHEK2 sequences were obtained by a standard protein BLAST (Altschul et al., 1997) , using the UniRef100 database (Suzek et al., 2015) . The sequences were selected to represent different evolutionary depths according to the sequence similarity of each homologous protein to human CHEK2 (the most distant homologous sequence was found in Caenorhabditis elegans). The selected sequences were aligned by using MUSCLE (Edgar, 2004) . EA estimated the fitness effect of variations by using an equation that states the phenotype change ( φ ∆ ) equals to the product of the sensitivity of the mutated site to genotype changes ( φ γ ∂ /∂ ) and the magnitude of the genotype change ( γ ∆ ). The sensitivity of the mutated site φ γ ∂ /∂ was approximated with the Evolutionary Trace algorithm which ranks the relative evolutionary importance of sequence positions in a family of aligned homologs (Lichtarge, Bourne, & Cohen, 1996) and the genotype change γ ∆ was approximated with inverse amino acid substitution log-odds. The computed fitness change ( φ ∆ ), or EA score, has been shown to correlate with experimental loss of function, clinical association, morbidity, and mortality (Katsonis & Lichtarge, 2014; Neskey et al., 2015) .
| Methodologies used by Group 2 (Vikas Pejaver, Predrag Radivojac, and Sean D. Mooney)
Available at http://mutpred.mutdb.org/#qform MutPred2 (Pejaver, Mooney et al., 2017) , an algorithm for the prediction of pathogenicity of missense variations (Pejaver, Urresti et al., 2017) was run on this data set to obtain scores between 0 and 1 representing the p (case). MutPred2 was run in the mode that uses gene-level homology count features. A score of 0 indicates a benign variation and a score of 1 indicates a pathogenic variation. The scores of MutPred2 approximate posterior probabilities (of pathogenicity, given sequence features). For each variant, this score was assumed to be equivalent to the probability that a variant is found in a case individual. Therefore, no further transformation of scores was performed.
| Methodologies used by Group 3 (Emidio Capriotti)
Various methods used available at http://biofold.org/resources.html For the CHEK2 challenge, we predicted the presence of a given variant in cohorts of participants and controls using three methods and combinations of them. The predictions from PhD-SNP (Capriotti, Calabrese, & Casadio, 2006) , PhD-SNPg and SNPs&GO (Capriotti et al., 2013; Capriotti, Martelli, Fariselli, & Casadio, 2017) variations. In addition, fuNTRp was also run on these variations. (Miller, Vitale, Rost, & Bromberg, 2019) The probability of each variation being more observed in the BC cohort was decided individually by assessing the reliability index (RI) of the SNAP prediction and the fuNTRp prediction. Specifically, a nonneutral SNAP variation at a toggle position was assigned a higher probability in the BC cohort and a higher p (case) value. A nonneutral SNAP variation at a rheostat or neutral position was assigned a p (case) closer to .5, and a neutral SNAP variation at a neutral position a p (case) of .5. A neutral SNAP variation at a rheostat or toggle position was assigned a score around .6 or .4. The allele frequencies of each variation in the general population were checked using ExAC, and if the variation had a relatively high variation (e.g. pI200T, MAF = 0.004), the p (case) was moved towards the healthy cohort (p = 0.3). If the variation was relatively rare, the p (case) was moved towards the BC cohort (p > .5). The distance the p (case) was moved depends manually on the confidence of SNAP and the fuNTRp prediction.
| Methodologies used by Group 5 (Pier Luigi
Martelli, Castrense Savojardo, Giulia Babbi, and Rita Casadio)
Available at http://snps.biofold.org/snps-and-go/snps-and-go.html
Submission 5.1
The predictions were based on SNPs&GO (Calabrese, Capriotti, Fariselli, Martelli, & Casadio, 2009 ). SNPs&GO is a method based on Support Vector Machines for the prediction of deleterious single amino acid polymorphisms (SAP) using protein functional annotation.
The output of SNPs&GO returns the effect (disease-associated variant or neutral variant) associated with a RI that is a number scoring from 0 (unreliable) to 10 (reliable). For each protein variant, the predictor scored the probability to be associated with human diseases. For the calibration of the final scores, a probability from .5 to 1 following a scale that is proportional to the RI of each prediction was assigned. When a variant is predicted to be neutral with an RI of 8, the predicted p = .5, when a variant is predicted to be disease associated with an RI of 8 the predicted p = 1. The maximum RI was set to 8 because this is the maximum RI found in this set of predictions. The prediction of one of the variants was manually curated because it was not coherent with the protein sequence.
UniProt accession O96017 reports in that position a different amino acid. Finally, all predictions were assigned an arbitrary standard deviation (SD) of 0.1.
Submission 5.2
The predictions are based on the disease Index matrix (Casadio, Vassura, Tiwari, Fariselli, & Luigi Martelli, 2011) . The matrix associates SAP with a corresponding probability to be associated with diseases (pd). For the calibration of the final scores, the pd values were scaled: considering neutral (prediction = 0.5) any SAP with a pd ≤ .4, and disease-related (prediction = 1) any SAP with a pd ≥ .8. All predictions were assigned an arbitrary SD of 0.1.
2.4.6 | Methodologies used by Group 6 (Yue Cao, Yuanfei Sun, and Yang Shen)
The training data set and the source code is available at: https:// github.com/Shen-Lab/WSR-PredictPofPathogenicity/ BRCA-interacting tumor suppressor genes variation data from StringDB at https://string-db.org/cgi/ were identified and downloaded along with those of BRCA1/2 from ClinVar at https://www.ncbi.nlm.nih. gov/clinvar/. In total, 2,026 variations of six tumor suppressors (CHEK2, BRCA1, BRCA2, BRIP1, RBBP8, and TP53) were collected. Using MutPred2, 15 features were extracted; together with a constant as the16th feature, used in linear regression with a tailored loss function (Cao et al., 2019) Specifically, to describe a penalty more in line with the real biological processes while reducing the complexity of the optimization, the loss function needs to be convex and first-order differentiable.
To accommodate these two conditions, a parabola-shaped polynomial of degree six as the loss function was implemented. The data is divided into five folds with four folds for training and one fold for testing and performed cross-validation of four-folds for optimizing the regularization constant C.
| Methodologies used by Group 7 (Aditi Garg, Debnath Pal)
Link to coarse-grained molecular dynamic simulation: http://pallab. cds.iisc.ac.in/CGMM/ Link to protein functional similarity match algorithm: http:// pallab.cds.iisc.ac.in/dynfunc/ Two templates from the PDB (3I6W, 2CN5) corresponding to CHEK2 (92-586 residues) were used to create a single model by multichain modeling using Modeller (Fiser & Sali, 2003) . The most stable structure was used to further create mutant models by replacing the specific amino acids. Each was subjected to C α atombased MD simulation for 1 microsecond with Coarse-Grained Molecular Mechanics force field (Bhadra & Pal, 2014) at 300 K in vacuum. Identical parameters were used for each simulation namely, steepest descent energy minimization (max. force ≤100 kJ·mol −1 ·nm −1 ). A single short sequence of 273-279 K simulated annealing in six steps was used within the 70 ps equilibration step before reference temperature coupling. Structures during unconstrained dynamics simulation were recorded every 100 ps time from which 11 frames at every 100 ns were used for finding flexible regions based on RMSF norm (Bhadra & Pal, 2014) . The filtered wild type protein and the variant pair were sent for a similarity score calculation using the formula: Similarity score = a/b, where a is the number of flexible regions in mutated protein and wild type (b). For residue positions, 1-91, a secondary structure was predicted using YASPIN (Lin, Simossis, Taylor, & Heringa, 2005) .
Variation located at a position with regular secondary structure was deemed as damaging, while others were benign; E → Q variation was treated as neutral. ATP binding is central to kinase activity and we found one segment (412-421) near this site which was flexible and could affect the ATP binding, and consequently the CHEK2 biochemical function. This segment was used in all variants for comparison and it was deemed that higher the similarity in flexibility of the variant protein to the wild type, the lesser are its chances to be damaging. The predicted similarity scores were normalized using identical reported cases from two previous studies for CHEK2 variants being damaging or benign (Desrichard, Bidet, Uhrhammer, & Bignon, 2011; Le Calvez-Kelm et al., 2011 ; Table S1 ). The ranges were mapped as follows: <70 damaging, 70-80 neutral, >80 benign for scores, and standard values of >.5 damaging, .5 neutral, <.5 benign for corresponding probabilities. 
Submission 8.2
This version applied the VAAST model with effect size estimates from (Young et al., 2016) for both truncating/splice-junction variants and missense variants "Overlap of missense analysis programs"; criteria). Known pathogenic variant information from ClinVar (Landrum et al., 2018) were also included. For any pathogenic variant reported in ClinVar, it was assumed that the probability of the alternative model was 1.
Submission 8.3
This version applied the VAAST model with used Align-GVGD variant effect sizes (Le Calvez-Kelm et al., 2011) and truncating/splicejunction estimates (Young et al., 2016) .
Submission 8.4
This version applied the VAAST model with fixed variant effect sizes (Cybulski et al., 2011; truncating/splice-junction OR 3.6 , causal missense OR 1.5 based on I157T).
Submission 8.5
Previously published estimates of CHEK2 variant effect size in BC as a function of one or more variant prioritization scores were applied. This version used effect size estimates (Young et al., 2016) truncating/splice-junction estimates (Young et al., 2016) .
| Methodologies for benchmarking
The data set of 34 CHEK2 SNVs was used to evaluate the 18 submission methods described above and compared with three existing techniques, used as reference, in the following ways:
1) A GLM which treats both the submissions and real experimental distinctions of variations as a continuous scale. The case/control participant data provided for each variant was used to compare each submission using a GLM with a GLM function in R (R Core Team, 2013) to calculate p values for each variant. As input, we provided the vector representing correct choices, where X was the participant category (case, control) and Y was the position as well as the entry per submission in the same format. The result was the intercept, standard error, t score, and p value. In addition, we obtained results for a subset of ten positions with more than one participant in at least one of the case or control group.
2) Analysis of the odds of pathogenicity was performed for participant data, clustered by each of the methodologies, as well as with BLOSUM62, Align-GVGD, and SIFT, into three groups, namely pathogenic, indeterminate, and benign. This method treats the submissions and the real experimental variations distinctions as categorical predictions. This assessment methodology identified the number of SNVs that each method categorized in benign, indeterminate, or pathogenic. To normalize across all methods the range of .45-.55 of p (case) were deemed indeterminate, p (case) values below that range were deemed benign and above were deemed pathogenic.
The analysis proceeded in three steps. First, the number of case and control participants for the SNVs that the submitter categorized in one of the three groups was used to an OR for each of the categories. VOSKANIAN ET AL.
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ORs were also estimated for protein truncating variants (4.61; not part of the CAGI competition, but the data were available to the analysis team) and for the overall set of rare missense substitutions (2.15). Second, we estimated a proportion of pathogenic variants for the benign, indeterminate, and pathogenic categories in each methodology. To do this, we used the total number of missense substitutions placed in the category along with the categorical OR, the OR for truncating variants (4.61) and a theoretical OR of 1.00 for "pure" set of benign variants. We then determined the ratio of variants with OR = 4.61 to variants with OR = 1.00 that best approximated the observed categorical OR. Third, we estimated the odds in favor of pathogenicity for the benign, indeterminate, and pathogenic categories in each methodology. To do this, we treated the (Table S2 ). Submission 8.3 and 8.4 generally made predictions in the neutral range, represented by the yellow color, while Submission 6 and 2 had most samples in the benign ranges, green. Submission 1, 5.1, 5.2, and 8.5 predicted most positions as pathogenic. Table 1 shows p values for the 18 submissions and the three reference methods, namely SIFT, BLOSUM62, and Align-GVGD as calculated using the GLM in R. The ten positions sub grouped are the ones with more than one participant difference between case or control categories, and at least two participants for that position thus giving us higher confidence in the assessment of those variant positions. The remaining 24 CHEK2 positions included in the "all positions" set were present in a total of only one participant, case or control. Method 8.6 lacks values for p values in the ten positions as all their p (case) values were the same not allowing for this type of analysis. The remaining results from the GLM analysis can be found in Table S3 . 
| DISCUSSION
The two methods of analysis, generalized linear modeling to assess in terms of p values and the odds of pathogenicity calculations, have their advantages but also several disadvantages. Both methods are impacted by the low number of datapoints in the original data set provided (Figure 1 ) and the unequal distribution of case and control instances. To account for some of this impact, we chose a subset of ten positions for the p value analysis. These ten positions all had more than one case that led to their classification as pathogenic or benign, giving us higher confidence on the statistical analysis. This subset of positions provided a framework where we no longer had zero participants in one category and just one in the other, but the data set was skewed, with a larger number of positions represented in case than in the control participant population.
Our results for the p value analysis in all positions and the subset of ten positions showed inconsistency in the performance of the methods. Five of the submitted methods (5.1, 3.1, 3.2, 2, and 3.3) and
Align-GVGD had significant p values when analyzed across all SNVs while only three submissions (5.1 and 4) and SIFT performed well across the ten positions. These results confirm that methods which categorize more positions in the pathogenic category perform better since both in the overall sample and particularly in the ten extracted positions, more BC participants were present. This further illustrates the benefits of prediction methods favoring pathogenic predictions.
Although, without a similar benchmarking data set that is more heavily benign, we could not assess whether this was just an artifact of the methods or an accurate bias towards the correct SNVs classification.
The reference methods, SIFT, Align-GVGD, and BLOSUM62, had some limitations in their evaluations. While BLOSUM62 and Align-GVGD have three categories, SIFT operates on a binary scale; this can explain why SIFT outperformed in the p values, among the ten positions, which with the exception of one were all confidently placed in case or control categories. BLOSUM62 as expected, being a simpler scoring, did very poorly.
To further understand the distribution of the p (case) submitted by each method, we had chosen three representative positions for each base (pathogenic, neutral, and protective; Figure 4 ). Thirteen groups predicted the pathogenic position correctly while only three called the protective variation correctly and nine called the neutral position correctly. The incorrect predictions generally fell in the pathogenic range, this may show some bias in how the methods evaluated the SNVs pathogenicity. This disbalance was also reflected in the data set provided. Based on the p (case) predictions for these three positions, Group 4 performed the most accurately.
We performed an alternative assessment of the submissions by analyzing the odds of pathogenicity, which focused on the overall number of variants in each of the three categories instead of the performance per variant as in the p value assessment.
As shown in our results (Figure 3) , Groups 3.1 and 8.3
performances were more closely correlated with the correct ACMG CI of pathogenicity. Even though our previous p value analysis indicated that Group 5.1 performed better, because they placed more positions in the pathogenic category, they performed worst in this analysis. The lack of range in some of the submitted method predictions, which is shown in the heatmap (Figure 2 ) is also clearly visible in Figure 3 . Thus, the groups that more heavily favored one side of the scale were more scrutinized in this method of analysis.
Also, many methods categorized the benign as indeterminate (range of 0.483-2.08). However, this could be an artifact of the preprocessing for this analysis. Due to the lack of consistent SDs across methods, we considered the arbitrary range of 0.45-0.55 to fall into the indeterminate category.
The pathogenicity odds results indicated that Align-GVGD was the best performer among the reference methods. However, this discrepancy may be due to SIFT relying on a binary classification and Align-GVGD having results that were more consistent with the challenge framework.
Regardless, Align-GVGD had a p value under .05 and performed well in the odds of pathogenicity analysis as did submissions by Groups 2 and 3.1, which utilized PhD-SNP, SNP&GO (Calabrese et al., 2009 ) and MutPred2 (Pejaver, Mooney et al., 2017) .
| CONCLUSIONS
The analysis methods used each had different advantages. While the GLM analysis provided an assessment of the methodʼs performance by specific positions and the classification it was given, the odds of pathogenicity assessed the overall classification of pathogenic, benign, and indeterminate positions. With relevance to the reference methods, Align-GVGD performed well overall, but not when estimating p values with the subset of 10 positions. From our assessment on this data set, which presented a strong bias towards pathogenic SNVs, it was difficult to extrapolate whether results would be different if the data set represented pathogenic and benign groups equally. We also concluded that it would be beneficial to perform this challenge and analysis with a larger, less biased data set. The comparison of these two results gave us a better idea of the correctness of the submissions, the appropriateness of the analysis method and the structure of the challenge.
